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Abstract
Aims: To investigate whether ginkgolide B (a platelet-activating factor inhibitor) affects vascular inflammation in
atherosclerosis-prone apolipoprotein E-deficient (ApoE
2/2) mice.
Methods and Results: Human platelets were used to evaluate the effects of ginkgolide B on platelet aggregation and signal
transduction. Ginkgolide B attenuated platelet aggregation and inhibited phosphatidylinositol 3 kinase (PI3K) activation and
Akt phosphorylation in thrombin- and collagen-activated platelets. ApoE
2/2 mice were administered a high-cholesterol diet
for 8 weeks. Plasma platelet factor 4 (PF4) and RANTES (regulated upon activation, normal T-cell expressed, and secreted
protein) were then measured using an enzyme-linked immunosorbent assay. Scanning electron microscopy and
immunohistochemistry were used to determine atherosclerotic lesions. Ginkgolide B decreased plasma PF4 and RANTES
levels in ApoE
2/2 mice. Scanning electron microscopic examination showed that ginkgolide B reduced aortic plaque in
ApoE
2/2 mice. Immunohistochemistry analysis demonstrated that ginkgolide B diminished P-selectin, PF4, RANTES, and
CD40L expression in aortic plaque in ApoE
2/2 mice. Moreover, ginkgolide B suppressed macrophage and vascular cell
adhesion protein 1 (VCAM-1) expression in aorta lesions in ApoE
2/2 mice. Similar effects were observed in aspirin-treated
ApoE
2/2 mice.
Conclusion: Ginkgolide B significantly reduced atherosclerotic lesions and P-selectin, PF4, RANTES, and CD40L expression in
aortic plaque in ApoE2/2 mice. The efficacy of ginkgolide B was similar to aspirin. These results provide direct evidence
that ginkgolide B inhibits atherosclerosis, which may be associated with inhibition of the PI3K/Akt pathway in activated
platelets.
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Introduction
Growing evidence has shown that platelets are involved in the
development of atherosclerosis. However, the contribution of
platelets to the process of atherosclerosis is not fully understood [1–
3]. Platelets are derived from megacaryocytes that possess
corpuscle-inflammatory properties. Platelets contain abundant a-
granules, dense-granules, and lysosomes where multiple bioactive
mediators are stored. Once platelets are activated, these bioactive
mediators are released into circulating blood and involved in
inflammatory responses.
Platelet factor 4 (PF4; also called CXCL4) belongs to the
chemokine family and is stored in platelet a-granules. PF4
accounts for approximately 25% of the proteins in platelet a-
granules [4]. PF4 enhances the degranulation of neutrophils
primed by tumor necrosis factor (TNF) and promotes their
adhesion to endothelial cells. It also enhances the binding of
oxidized low-density lipoprotein (LDL) to the LDL receptor on
macrophages, human umbilical vein endothelial cells, and vascular
smooth muscle cells [5–7].
RANTES (regulated upon activation, normal T-cell expressed,
and secreted, CCL5) is another inflammatory mediator stored in
platelet a-granules and a soluble 7.8 kDa chemokine. Activated
platelets can deposit RANTES on the surface of monocytes or
atherosclerotic endothelial cells in a P-selectin-dependent process
[8,9]. A recent study reported that blockade of the RANTES
receptor attenuates neointima formation and macrophage in-
filtration in apolipoprotein E-deficient (ApoE
2/2) mice [10].
Ginkgolide B, an herbal extract from the leaves of the Ginkgo
biloba tree, is a natural inhibitor of platelet-activating factor (PAF).
Previous studies have indicated that ginkgolide B can suppress
PAF-mediated platelet activation by competitively binding to the
PAF receptor [11,12]. Our previous studies found that ginkgolide
B can suppress oxidized LDL-induced inflammatory protein
expression and inhibit nuclear factor-kB (NF-kB) activation in
human endothelial cells [13,14]. However, still unclear is whether
ginkgolide B can reduce inflammatory mediators released by
platelets in atherosclerosis. The aim of the present study was to
evaluate the effects of ginkgolide B on vascular inflammation and
atherosclerotic plaque in atherosclerosis-prone ApoE
2/2 mice.
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Ethics statement
All of the animal experiments were approved by the In-
stitutional Animal Care and Application Committee of the Beijing
Institute of Geriatrics (approval no. 20081018), and the in-
vestigation conformed with the Guide for the Care and Use of
Laboratory Animals published by the United States National
Institutes of Health. For the cellular experiments, blood was
collected from healthy donors, from whom we received informed
consent. The experiment was approved by the Ethics Committee
of the Beijing Institute of Geriatrics (approval no. 20081019).
Materials
Ginkgolide B was purchased from Daguanyuan Company
(Xuzhou, China) and had a purity of 95%. PF4 and RANTES
enzyme-linked immunosorbent assay (ELISA) kits were purchased
from R&D Systems (Minneapolis, MN, USA). Anti-PI3K and
anti-Akt antibodies were purchased from Cell Signaling Technol-
ogies (Danvers, MA, USA). Anti-P-selectin, anti-RANTES, and
anti-PF4 antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). LY294002 was purchased from
Sigma-Aldrich (St. Louis, MO, USA). CD40L antibodies were
purchased from Abcam (Boston, MA, USA).
Plasma PF4, RANTES and Plasma Lipid Measurement
Blood samples were taken by cardiac aspiration after the mice
were anesthetized with 1.5% isoflurane. Blood was collected in
ethylenediaminetetraacetic acid-coated tubes and centrifuged at
25006g for 15 min at 4uC. Plasma samples were stored at 220uC.
Plasma PF4 and RANTES content was assayed using ELISA kits
according to the manufacturer’s instructions. Plasma lipid levels
were measured by enzymatic method using AU5400 Chemistry
System from Beckman Coulter (Kraemer Boulevard Brea, CA,
USA).
Platelet Aggregation Analysis
Citrate anti-coagulated venous blood was obtained from human
donors who had not taken any medication for a minimum of
2 weeks before collection. The blood was centrifuged at 4006g for
15 min to obtain platelet-rich plasma. The platelets were washed
twice in Tyrode/HEPES buffer with 2 mM ethylene glycol
tetraacetic acid (EGDA) and resuspended in Tyrode/HEPES
buffer at a concentration of 1610
8 cells/ml. Platelet aggregation
was assessed using a CHRONO-LOG aggregometer.
Western Blot
Cell lysates were analyzed with sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and electrotransferred to polyviny-
lidene fluoride membranes. The membranes were blocked with
1% bovine serum albumin and then incubated with specific
antibodies. After three washes in Tris phosphate-buffered saline
(TPBS) that contained 0.5% Tween 20 in PBS, the membranes
were incubated with horseradish peroxidase-conjugated secondary
antibodies in TPBS. The bands were detected by chemilumines-
cent detection reagents. Blot densitometry was then performed,
and the bands were analyzed using a Gene Genius Bio Imaging
System.
Animal Experiments
Eight-week-old male ApoE
2/2 mice (C57/B16 genetic back-
ground) were obtained from the Experimental Animal Laboratory
of Beijing University (Beijing, China). ApoE
2/2 mice were fed
a high-fat diet that contained 20% fat and 1.25% cholesterol. The
mice were randomly divided into three groups (n=12 per group).
The mice were given vehicle (0.3 ml PBS/day; control group) or
ginkgolide B (0.6 mg/day) or aspirin (0.5 mg/day) by intragastric
administration for 8 weeks. The mice were housed in a room with
a 12 h/12 h light/dark cycle and allowed free access to food and
water. At the end of the experiments, the animals were sacrificed,
and blood samples were collected and analyzed.
Imaging of Aorta Surface Characteristics in Mice Using an
Environmental Scanning Electron Microscope
The mice were sacrificed after being fed high-cholesterol chow
for 8 weeks. The aortic tree was perfused for 10 min with PBS.
Following the removal of the surrounding adventitial tissue, the
aorta was opened longitudinally from the aortic root and fixed
with 2.5% glutaraldehyde overnight. The aorta was then washed
three times with PBS. The aorta was fixed with OsO4 for 4 h,
washed three times with PBS, and then dehydrated using various
concentrations of ethanol. Finally, the aorta was adhered to
carbon-conductive adhesive on the tray. The characteristics of the
aorta surface were imaged using an environmental scanning
electron microscope (FEI QUANTA 200).
Atherosclerotic Lesion Size Determination
The proximal part of the thoracic aorta to the aortic origin
was isolated from adherent connective tissue and then cleaned.
The atherosclerotic plaque area was quantified by analyzing the
open luminal surface image of the formalin-fixed aortic arch
Figure 1. Effect of ginkgolide B on platelet aggregation
induced by thrombin and collagen. Various concentrations of
ginkgolide B were preincubated with platelets at 37uC for 5 min.
Platelet aggregation was then induced by thrombin (0.5 U/ml) or
collagen (10 mg/ml). (A) Thrombin-induced platelet aggregation. (B)
Collagen-induced platelet aggregation. The data were obtained from
five experiments.
doi:10.1371/journal.pone.0036237.g001
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clearly distinguishable from the non-plaque-covered areas on the
luminal surface of the vessels without staining. The colored
images were acquired with a Sony digital camera mounted on
a microscope (Olympus BX60). The data analysis was
performed using image analysis software (Simple, Compix,
Mars, PA, USA), and the same setting was retained for the
analysis of each group.
Immunohistochemistry
The mice were euthanized with 1.5% isoflurane, and the aorta
was dissected, opened longitudinally from the heart to iliac
arteries, and stained with Oil Red O to determine the lesion area.
Specimens that contained the aortic root, aortic arch, thoracic
aorta, and abdominal aorta were immersed for 3 s in 60%
isopropanol and stained for 10 min in a saturated Oil Red O
solution. The specimens were then rinsed in 60% isopropanol for
1 min and washed three times. The aortic root specimens were
dissected under a microscope, fixed in a 4% formaldehyde
solution, and frozen in an optimal-cutting-temperature embedding
medium for serial cryosectioning that covered 0.8 mm of the root.
The cryosections (7 mm) were examined with Oil Red O staining
and immunohistochemistry. The average immunohistochemical
staining with various antibodies (i.e., PF4, RANTES, CD40L,
MAC-3, P-selectin, and vascular cell adhesion protein 1 [VCAM-
1]) was assessed from multiple samples of each artery. Bound
antibody was detected with a DAB substrate kit (Beijing
Zhongshan Golden Bridge Biotechnology, Beijing, China). Semi-
quantitative immunostaining analysis was performed using an
Olympus microscope linked to the ImagePro Plus image analysis
system (Media Cybernetics, Bethesda, MD, USA).
Statistical Analysis
The data are expressed as mean 6 SEM. Statistical analyses
were performed using independent t-tests and analysis of variance
(ANOVA) followed by the Tukey post hoc test. The results were
considered significant at values of p,0.05.
Results
Ginkgolide B Inhibits Platelet Aggregation
In the present study, we first examined whether ginkgolide B
inhibits platelet aggregation induced by thrombin and collagen. As
shown in Fig. 1, platelets pretreated with ginkgolide B (0.2, 0.4,
and 0.6 mg/ml) for 5 min exhibited impaired aggregation ability.
Ginkgolide B (0.6 mg/ml) significantly inhibited thrombin- and
collagen-induced platelet aggregation. The inhibitory ratio was
43.2% for thrombin-induced platelet aggregation and 51.3% for
collagen-induced platelet aggregation.
Effects of Ginkgolide B on PI3K and Akt Phosphorylation
The PI3K signaling pathway includes a group of enzymes that
generate lipid second messengers to mediate multi-signal trans-
duction. The PI3K pathway is involved in thrombin- and
collagen-induced platelet activation. To investigate the effects of
ginkgolide B on human platelet activation, we first determined
PI3K 110b expression and Akt phosphorylation. As shown in
Fig. 2A, PI3K expression was slightly increased in stimulated
Figure 2. Effect of ginkgolide B on PI3K expression and Akt phosphorylation in activated platelets. Washed platelets were pretreated
with various concentrations of ginkgolide B or LY294002 for 5 min. Platelet activation was then challenged by thrombin (0.5 U/ml) and collagen
(10 mg/ml). Western blot analysis of PI3K expression and Akt phosphorylation in thrombin- and collagen-activated platelets is shown. (A) Ginkgolide B
had no significant effect on PI3K expression in activated platelets. (B) Ginkgolide B blocked Akt phosphorylation in activated platelets. (C) Ly294002
inhibited Akt phosphorylation in activated platelets. (D) The combination of low concentrations of ginkgolide B and Ly294002 completely inhibited
Akt phosphorylation. The results were obtained from three independent experiments.
doi:10.1371/journal.pone.0036237.g002
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ginkgolide B had no significant effect on PI3K expression. Akt
phosphorylation was then examined. As shown in Fig. 2B, both
thrombin and collagen challenged Akt phosphorylation in
activated platelets. Ginkgolide B significantly and dose-depen-
dently decreased Akt phosphorylation in thrombin- and collagen-
activated platelets. We then investigated the effect of LY294002,
a specific PI3K inhibitor, on Akt phosphorylation in activated
platelets. As shown in Fig. 2C, LY294002 dose-dependently
inhibited Akt phosphorylation in thrombin- and collagen-activated
platelets. Furthermore, we used low concentrations of LY294002
and ginkgolide B that failed to fully attenuate Akt phosphorylation
alone. As shown in Fig. 2D, the combination of low concentrations
of LY294002 and ginkgolide B completely abolished Akt
phosphorylation, suggesting that inhibition of Akt phosphorylation
by ginkgolide B might occur via inhibition of PI3K activation. We
then determined whether ginkgolide B can inhibit platelet release
in activated platelets.
Analysis of Platelet Release
We then determined the effects of ginkgolide B on platelet
release induced by thrombin and collagen. The supernatant was
collected after platelets were stimulated by thrombin or collagen as
described in the Methods. As shown in Fig. 3, treatment with
0.6 mg/ml ginkgolide B potently attenuated CD40L and
RANTES release in platelets activated by thrombin and collagen.
In the experiment, albumin was used as a reference object for the
platelet release response.
Ginkgolide B Inhibits Aortic Atherosclerotic Lesion Area
To evaluate whether ginkgolide B influences atherosclerosis, we
first observed the characteristics of the aorta surface in ApoE
2/2
mice with 8 weeks of treatment using a scanning electron
microscope. As expected, lesion development was seen at the
end of the 8-week high-cholesterol diet. As shown in Fig. 4A,
a large number of plaques appeared on the surface of the aorta in
ApoE
2/2 mice. In contrast, aortic plaques were reduced in both
ginkgolide B- and aspirin-treated ApoE
2/2 mice. Moreover, we
used Oil Red O staining of the aorta in each group. As shown in
Figure 3. Effect of ginkgolide B on CD40L and RANTES levels in platelets activated by thrombin and collagen. The levels of CD40L and
RANTES were determined by Western blot. The results were obtained from three independent experiments.
#p,0.05, vs. without treatment of
platelets; *p,0.05, vs. treatment with thrombin alone.
doi:10.1371/journal.pone.0036237.g003
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Scanning electron microscope image of atherosclerotic lesion in each group (n=3 per group). (B) Representative en face Oil Red O staining of aorta
and quantitative analysis of whole aorta lesion in each group. The percentage lesion area was quantitatively analyzed in each group (n=3 per group).
(C) Representative Oil Red O-stained cross-sections from the aortic root in each group. The sections were chosen from mice whose average lesion
area approximated the mean value for that group, and the sections shown were obtained at approximately the same level of the aortic root (original
magnification, 406). The percentage lesion area was quantified in each group (n=10 per group).
doi:10.1371/journal.pone.0036237.g004
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treated group and 63.2% in the aspirin-treated group compared
with the control group. Oil Red O-stained serial cross-sections of
the aorta showed that the plaque area of the aortic root decreased
by 67.2% in the ginkgolide B-treated group and 65.5% in the
aspirin-treated group (Fig. 4C). These results provide direct
evidence that ginkgolide B and aspirin have protective effects
against atherosclerosis in ApoE
2/2 mice.
Effects of Ginkgolide B on Plasma Lipid Levels
The mice were fed a high-fat diet for 8 weeks, and plasma lipid
levels were analyzed. As shown in Table 1, no significant
differences in lipid levels were found between the control group
and ginkgolide B-treated group or between the control group and
aspirin-treated group. However, significant differences in the levels
of TC, TG, and LDL were observed between the ginkgolide B-
treated group and aspirin-treated group (P,0.05).
Effects of Ginkgolide B on Plasma PF4 and RANTES
Platelets become activated at the site of vascular injury and
secrete their a-granule and dense-granule contents under condi-
tions of atherosclerosis and high lipidemia. Plasma PF4 and
RANTES levels were detected by ELISA in the present study. As
shown in Fig. 5, ginkgolide B potently reduced the level of PF4 by
62.4% in plasma in ApoE
2/2 mice compared with the control
group. Aspirin also decreased the level of PF4 by 25%. Ginkgolide
B abolished the increase in RANTES. Compared with the control
group, ginkgolide B reduced RANTES by 46.1%, and aspirin
decreased RANTES by 69.2%. These results suggest that the
ginkgolide B- and aspirin-induced decreases in the levels of PF4
and RANTES might be associated with platelet function in-
hibition.
Effect of Ginkgolide B on Macrophage and VCAM-1
Expression in Plaque
To investigate the effects of ginkgolide B on vascular in-
flammation in atherosclerosis, immunohistochemical analysis was
performed in the aortic root in ApoE
2/2 mice. The Mac-3
antibody was used for staining macrophages in the aortic root in
ApoE
2/2 mice. We used IPP6.0 software to determine the
abundance of macrophages in plaque from three ApoE
2/2 mice.
As shown in Fig. 6A, compared with the control group, ginkgolide
B decreased the macrophage distribution by 50.0% in Ape E
2/2
mice, and aspirin decreased the macrophage distribution by
59.3% in ApoE
2/2 mice. We then examined VCAM-1 expression
in aortic plaque. VCAM-1 expression was reduced by 58.4% in
aortic plaque in the ginkgolide B-treated group and 60.4% in the
aspirin-treated group (Fig. 6B). These results indicate that
ginkgolide B and aspirin suppressed vascular inflammation in
ApoE
2/2 mice.
Effect of Ginkgolide B on P-selectin, PF4, RANTES, and
CD40L in Plaque
We also investigated whether ginkgolide B can abolish P-
selectin, PF4, RANTES, and CD40L expression in plaque in
ApoE
2/2 mice. As shown in Fig. 7, both ginkgolide B and aspirin
attenuated the plaque expression of these four inflammatory
proteins in ApoE
2/2 mice. Compared with the control group, P-
selectin expression in plaque was decreased by 63.4% in the
ginkgolide B-treated group and 58.3% in the aspirin-treated
group. PF4 expression was decreased by 54.7% in ginkgolide B-
treated ApoE
2/2 mice and 39.2% in aspirin-treated ApoE
2/2
mice. RANTES expression was decreased by 51.8% in the
ginkgolide B-treated group and 58.8% in the aspirin-treated
group. CD40L expression was decreased by 66.4% in ginkgolide
B-treated ApoE
2/2 mice and 76.9% in aspirin-treated ApoE
2/2
mice. These results suggest that both ginkgolide B and aspirin can
suppress inflammatory protein expression in plaque in ApoE
2/2
mice, an effect that is likely attributable to the inhibition of platelet
function.
Table 1. Effects of ginkgolide B or aspirin on plasma lipid
levels in ApoE
2/2 mice.
Group n TC TG HDL-C LDL-C
control 10 11.4262.87 0.7160.30 0.5360.11 3.4361.13
ginkgolide B 10 9.8761.49* 0.5560.17* 0.5860.12 2.7560.63*
aspirin 10 13.0261.89 0.7360.18 0.5660.18 3.9260.80
Values are in mmol/L (mean6SEM). There were no differences between
ginkgolide B group and control or aspirin group and control. *P,0.05,
ginkgolide B group vs aspirin group.
doi:10.1371/journal.pone.0036237.t001
Figure 5. Plasma PF4 and RANTES content was detected by ELISA in each group. All of the mice were administered a high-cholesterol diet
for 8 weeks. The data are expressed as mean 6 SEM. **p,0.001, vs. ApoE
2/2 mice; *p,0.05, vs. control group.
doi:10.1371/journal.pone.0036237.g005
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We then determined whether ginkgolide B has similar effects on
the PI3K/Akt pathway in ApoE
2/2 mice. We collected platelets
from ApoE
2/2 mice to evaluate the effect of ginkgolide B on Akt
phosphorylation in activated platelets. As shown in Fig. 8, Akt
phosphorylation was induced in platelets activated by thrombin
and collagen. Moreover, concentrations of 1 mM LY294002 and
0.4 mg/ml ginkgolide B alone partially inhibited Akt phosphor-
ylation. The combination of low concentrations of LY294002 and
ginkgolide B potently abolished Akt phosphorylation. The results
suggest that ginkgolide B inhibits platelet activation in ApoE
2/2
mice via a similar mechanism.
Ginkgolide B Inhibits Platelet Aggregation in
Atherosclerotic Lesion
Platelet aggregation was observed in atherosclerotic plaque
using a scanning electron microscope. As shown in Fig. 9, many
platelets aggregated on the atherosclerotic lesion in ApoE
2/2
mice. In contrast, few platelets accumulated on plaques in
ginkgolide B- and aspirin- treated ApoE
2/2 mice. The image
provides a visual representation of the platelets involved in
atherosclerosis.
Discussion
The present study investigated whether ginkgolide B can
decrease the development of atherosclerosis. Aspirin is widely
used for its anti-platelet function and is an irreversible cycloox-
ygenase-1 inhibitor. Recent studies have indicated that aspirin can
reduce atherosclerotic lesions and serum TXA2 levels in ApoE
2/2
mice [15,16]. Therefore, the effect of ginkgolide B was compared
with aspirin on atherosclerosis in ApoE
2/2 mice. The scanning
electron microscope and Oil Red O staining results showed that
both ginkgolide B and aspirin significantly reduced atheromatous
plaque in ApoE
2/2 mice. Macrophages and the inflammatory
protein VCAM-1 were also proportionally decreased in athero-
matous plaque in ApoE
2/2 mice. Furthermore, the results showed
that ginkgolide B and aspirin decreased PF4 and RANTES levels
in plasma. Immunohistochemistry showed that both ginkgolide B
and aspirin significantly reduced these inflammatory proteins in
aortic plaque in ApoE
2/2 mice. Ginkgolide B appeared to have
better inhibitory effects on PF4 expression in plaque, and aspirin
had stronger effects on RANTES expression in plaque. These
results suggest that the mechanism of platelet function inhibition
by ginkgolide B is distinct from the mechanism of aspirin in vivo.
The effects of ginkgolide B on the inhibition of platelet function
were investigated in the present study. Ginkgolide B significantly
inhibited platelet aggregation induced by thrombin and collagen.
The PI3K pathway has been shown to play an important role in
collagen- and thrombin-induced platelet activation [17,18]. Pre-
vious studies showed that thrombin stimulates platelet a-granule
release via the PI3K pathway [19,20]. Recent studies provided
evidence of the crucial role of the PI3K family in the regulation of
inflammation within the vasculature during atherogenesis, such as
inflammatory cell recruitment and the expression and activation of
inflammatory mediators. The results showed that ginkgolide B
abolished Akt phosphorylation by inhibiting PI3K activation,
whereas ginkgolide B had no effects on PI3K expression. These
results may indicate that changes in protein expression may
require a longer time to develop in cells. The PI3K family contains
various subunits, such as classes IA, IB, II, and III. The precise
regulation of PI3K by ginkgolide B needs further study.
Additionally, the inhibitory effect of ginkgolide B on Akt
phosphorylation was also confirmed in ApoE
2/2 mice.
Our results also demonstrated that ginkgolide B decreased
CD40L and RANTES levels in platelet release products.
RANTES is upregulated at sites of vascular inflammation. As
a potent chemoattractant, it also mediates monocyte and T-
lymphocyte migration through endothelial cell-cell junctions.
RANTES receptor antagonists can reduce atherosclerotic plaque
formation in mice [21,22]. CD40 is a transmembrane receptor of
Figure 6. Effect of ginkgolide B and aspirin on macrophage and VCAM-1 expression in plaque in Apo
2/2 mice. (A) Macrophage
expression in plaque in ApoE
2/2 mice. (B) VACM-1 expression in ApoE
2/2 mice. The cross-sections were from the aortic root in each group, and these
were chosen from mice whose average lesion area approximated the mean value for that group. The sections shown were obtained at approximately
the same level of the aortic root (original magnification, 406). The percentage lesion area was quantified in each group (n=6 per group). *p,0.05, vs.
control group.
doi:10.1371/journal.pone.0036237.g006
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CD40 ligand (CD40L) is derived from platelets. CD40L enhances
inflammation by promoting the release of cytokines, chemokines,
and cell-cell interactions [23,24]. A recent study elucidated a novel
alternative pathway for CD40L-mediated inflammation that
formed interactions with the monocyte/macrophage integrin
Mac-1 [25]. PF4 promotes monocyte survival, induces monocyte
differentiation into macrophages, and accelerates the formation of
foam cells in atherosclerosis [26]. P-selectin is a cell surface
adhesion molecule that plays an essential role in the initial
recruitment of leukocytes to the site of injury during inflammation
[27]. P-selectin has been detected on the surface of endothelia at
all stages of atherosclerotic lesion development in humans and
animal models of atherosclerosis. Some studies showed that anti-P-
selectin antibodies inhibit monocyte rolling on the endothelium of
carotid arteries isolated from ApoE
2/2 mice. The absence of P-
selectin delays fatty streak formation in mice [28,29]. The present
results provide direct evidence that ginkgolide B represses
atherosclerosis by attenuating P-selectin, RANTES, CD40L, and
PF4 expression in plaque in ApoE
2/2 mice, with efficacy similar
to aspirin.
Our data demonstrated that platelets are involved in athero-
sclerosis, and ginkgolide B inhibited inflammation by attenuating
platelet release. The precise mechanism of action and possible
clinical applications will need to be addressed in future studies.
The effects of ginkgolide B on the stability and accumulation of
plaque should also be further evaluated at different time-points in
the development of atherosclerosis.
Figure 7. Immunohistochemical analysis of P-selectin, PF4, RANTES, and CD40 expression in plaque in ApoE
2/2 mice. The cross-
sections were from the aortic root in each group, and these were chosen from mice whose average lesion area approximated the mean value for that
group. The sections shown were obtained at approximately the same level of the aortic root (original magnification, 406). The percentage lesion area
was quantified in each group (n=6 per group). *p,0.05, vs. control group.
doi:10.1371/journal.pone.0036237.g007
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2/2 mice. Washed platelets in ApoE
2/2 mice were
pretreated with 1 mM LY294002 or 0.4 mg/ml ginkgolide B for 5 min, and platelet activation was then challenged by 0.5 U/ml thrombin or 10 mg/ml
collagen. The results were obtained from three independent experiments.
doi:10.1371/journal.pone.0036237.g008
Figure 9. Effect of ginkgolide B on platelet aggregation on atherosclerotic lesion in ApoE
2/2 mice. The mice were sacrificed after being
fed high-fat chow for 8 weeks. Platelet aggregation on atherosclerotic lesions was observed in each group using a scanning electron microscope.
Arrows indicate platelet accumulation.
doi:10.1371/journal.pone.0036237.g009
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The present results provide direct evidence that ginkgolide B
can attenuate inflammatory protein expression in plaque in
ApoE
2/2 mice. The mechanisms might include the abolition of
P-selectin, RANTES, PF4, and CD40L expression. These in-
flammatory mediators are closely related to platelet release. These
results suggest that ginkgolide B can attenuate atherosclerosis in
ApoE
2/2 mice and inhibit platelet release by blocking the PI3k/
Akt pathway in thrombin- and collagen-activated platelets. These
results also suggest the therapeutic potential of ginkgolide B in the
prevention and treatment of atherosclerosis.
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